Therapeutic application of histone deacetylase inhibitors for central nervous system disorders

By A. Kazantsev, Leslie M. Thompson. Nature reviews. Drug discovery, 2008

724 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Molecular mechanisms and potential therapeutical targets in Huntington's disease. (2010, background): “Several studies have shown that some of the reported ameliorative effects of HDACi can be mediated also by effects that go beyond the rescue of mRNA abnormalities (299).”
An epigenetic blockade of cognitive functions in the neurodegenerating brain (2012, background): “Accordingly, pharmacological treatments aimed at increasing histone acetylation have shown promising results in reversing cognitive deficits in some of these models, predominantly by the use of non-selective histone deacetylase (HDAC) inhibitor”
Human Disease-Drug Network Based on Genomic Expression Profiles (2009, background): “It has been shown that some cancer drugs in combination with AIDs drugs halt the progress of Huntington’s in fruit flies [42,43].”
Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes (2009, background): “However, the drug development community faces significant challenges in the selection and design of drugs for clinical candidates, partially because of the lack of known targets of HATs and HDACs (Kazantsev and Thompson, 2008).”
Somatic retrotransposition alters the genetic landscape of the human brain (2011, background): “For instance, HDAC1 is a genome-wide transcriptional regulator that controls the canonical L1 promoter 4,25 and is implicated in psychiatric disease and tumorigenesis 26 .”